Prolactinoma Market: How Is Cabergoline Resistance and Dopamine...

ha aggiunto una foto Health

2026-07-02 10:32:51 -

Prolactinoma Market: How Is Cabergoline Resistance and Dopamine Agonist-Intolerant Patient Management Creating New Therapeutic Opportunities?

Prolactinoma — the benign pituitary adenoma arising from lactotroph cells causing hyperprolactinemia, galactorrhea, amenorrhea, infertility, and mass effect symptoms including headache and visual field defects — represents the most common functioning pituitary tumor requiring chronic pharmacological management, with the Prolactinoma Market reflecting dopamine agonist therapy and...

0 Commenti 0 condivisioni 9 Views 0 Anteprima